Details of the Drug Combination

General Information of Drug Combination (ID: DC4FEFD)

Drug Combination Name
PMID25656651-Compound-7 Paclitaxel
Indication
Disease Entry Status REF
Breast Cancer Phase 1 [1]
Component Drugs PMID25656651-Compound-7   DMK3TMD Paclitaxel   DMLB81S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
PMID25656651-Compound-7 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Paclitaxel
Disease Entry ICD 11 Status REF
Breast carcinoma N.A. Approved [2]
Cutaneous melanoma 2C30 Approved [2]
Cutaneous squamous cell carcinoma 2C30 Approved [2]
Epithelial ovarian cancer 2B5D Approved [2]
Extragonadal germ cell tumor N.A. Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Inflammatory breast cancer 2C62 Approved [2]
Kaposi sarcoma 2B57 Approved [2]
Lung adenocarcinoma N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Ocular hypertension 9C61.01 Approved [2]
Ovarian neoplasm N.A. Approved [2]
Ovarian serous cystadenocarcinoma N.A. Approved [2]
Pain MG30-MG3Z Approved [2]
Pancreatic ductal carcinoma 2C10.0 Approved [2]
Primary peritoneal carcinoma N.A. Approved [2]
Testicular germ cell tumor N.A. Approved [2]
Urethral cancer 2C93 Approved [2]
Lung large cell carcinoma N.A. Investigative [2]
Paclitaxel Interacts with 11 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [17]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [18]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [19]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [20]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [21]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [22]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [23]
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [24]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [25]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [26]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DTP(s)
Paclitaxel Interacts with 478 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Expression [28]
ATP-binding cassette sub-family C member 10 (ABCC10) OT2JRWWJ MRP7_HUMAN Increases Expression [29]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [29]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Response To Substance [30]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [31]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [32]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Response To Substance [33]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Transport [21]
Cyclin-dependent kinase 20 (CDK20) OTOLNN68 CDK20_HUMAN Decreases Expression [34]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Increases ADR [4]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Increases ADR [4]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [35]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [36]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Decreases Expression [34]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [37]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [37]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [9]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [4]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [38]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Increases Activity [39]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [40]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [5]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Decreases Activity [41]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [42]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Decreases Expression [35]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [35]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [43]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Decreases Activity [43]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [43]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [44]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [45]
DNA fragmentation factor subunit alpha (DFFA) OTFPFMT8 DFFA_HUMAN Decreases Expression [7]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Decreases Expression [6]
Serine/threonine-protein kinase PLK4 (PLK4) OTV8KZDZ PLK4_HUMAN Decreases Expression [6]
TNF receptor-associated factor 5 (TRAF5) OTSBTLO0 TRAF5_HUMAN Decreases Expression [6]
Myc box-dependent-interacting protein 1 (BIN1) OTK8O0X8 BIN1_HUMAN Increases Expression [46]
Nucleoside diphosphate kinase, mitochondrial (NME4) OT2JTT42 NDKM_HUMAN Decreases Expression [7]
Potassium channel subfamily K member 3 (KCNK3) OTWMAV6G KCNK3_HUMAN Increases Expression [7]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Increases Expression [37]
Acyl-coenzyme A thioesterase 8 (ACOT8) OTHY684G ACOT8_HUMAN Decreases Expression [47]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [48]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [45]
Neuropilin-1 (NRP1) OTCGULYV NRP1_HUMAN Increases Expression [46]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Increases Expression [49]
Mitogen-activated protein kinase 13 (MAPK13) OT0W9GE7 MK13_HUMAN Increases Expression [7]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [50]
High affinity copper uptake protein 1 (SLC31A1) OTXLRTUB COPT1_HUMAN Increases Expression [29]
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Increases Expression [29]
N-glycosylase/DNA lyase (OGG1) OTJ97TF3 OGG1_HUMAN Increases Expression [7]
Retinoschisin (RS1) OTEW1ZM5 XLRS1_HUMAN Decreases Secretion [51]
Kunitz-type protease inhibitor 2 (SPINT2) OTQV7BKQ SPIT2_HUMAN Decreases Expression [46]
Adenylate cyclase type 6 (ADCY6) OTFOY4WW ADCY6_HUMAN Decreases Expression [6]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [49]
Mitotic checkpoint protein BUB3 (BUB3) OTU91HAU BUB3_HUMAN Increases Expression [7]
Phospholipid phosphatase 2 (PLPP2) OT0BQAXX PLPP2_HUMAN Decreases Expression [46]
Myelin protein zero-like protein 2 (MPZL2) OTKFNDUI MPZL2_HUMAN Decreases Expression [46]
Dual specificity protein phosphatase CDC14B (CDC14B) OTAESVOZ CC14B_HUMAN Decreases Expression [34]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [52]
Death effector domain-containing protein (DEDD) OTIL349E DEDD_HUMAN Decreases Expression [6]
Serine hydrolase RBBP9 (RBBP9) OT0Z04L6 RBBP9_HUMAN Decreases Expression [6]
Tumor necrosis factor ligand superfamily member 13 (TNFSF13) OT90OWIO TNF13_HUMAN Increases Expression [34]
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial (CLPX) OTIT4JL0 CLPX_HUMAN Increases Expression [7]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [34]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Affects Expression [53]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [6]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Decreases Expression [54]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [34]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [7]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Expression [34]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [55]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [46]
Collagen alpha-1(IV) chain (COL4A1) OTL6D1YE CO4A1_HUMAN Increases Expression [46]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [56]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Phosphorylation [57]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [58]
Thy-1 membrane glycoprotein (THY1) OTVONVTB THY1_HUMAN Increases Expression [46]
Apolipoprotein D (APOD) OTT77XW8 APOD_HUMAN Increases Expression [46]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA) OTWJTCRK PCCA_HUMAN Decreases Expression [7]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [52]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [59]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [60]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [61]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Expression [62]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [63]
Gelsolin (GSN) OT4KS2UU GELS_HUMAN Decreases Expression [6]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Phosphorylation [64]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [34]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Decreases Expression [47]
Prosaposin (PSAP) OTUOEKY7 SAP_HUMAN Decreases Expression [6]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Increases Expression [46]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [46]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [65]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [59]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Localization [66]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [67]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [68]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [68]
Collagen alpha-1(VI) chain (COL6A1) OTYKSCOB CO6A1_HUMAN Increases Expression [46]
Collagen alpha-2(VI) chain (COL6A2) OTQC6PPO CO6A2_HUMAN Increases Expression [46]
ADP/ATP translocase 1 (SLC25A4) OTKYLK2J ADT1_HUMAN Decreases Expression [6]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Decreases Expression [10]
Elongation factor 2 (EEF2) OTZ7SZ39 EF2_HUMAN Decreases Expression [6]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases Expression [69]
Interleukin-1 receptor type 1 (IL1R1) OTTU8959 IL1R1_HUMAN Decreases Expression [7]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Increases Expression [70]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [71]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [46]
Integrin beta-6 (ITGB6) OTI3DJ7U ITB6_HUMAN Decreases Expression [46]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [52]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [6]
Sodium/hydrogen exchanger 1 (SLC9A1) OT6HNHFV SL9A1_HUMAN Decreases Activity [72]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [60]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [46]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [34]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Increases Expression [59]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) OTBZKX4P ROA2_HUMAN Decreases Expression [6]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [46]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [47]
Follicle-stimulating hormone receptor (FSHR) OT9MVMLI FSHR_HUMAN Decreases Expression [10]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [68]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Activity [73]
Signal transducer CD24 (CD24) OT7CODJ4 CD24_HUMAN Decreases Expression [46]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [74]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [46]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Increases Expression [46]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [10]
Long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL) OTP7Y0UF ACADL_HUMAN Decreases Expression [7]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Expression [55]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [34]
Adenylosuccinate synthetase isozyme 2 (ADSS2) OTW26XXB PURA2_HUMAN Decreases Expression [7]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Increases Phosphorylation [75]
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1) OTFRWOLM HNRH1_HUMAN Decreases Expression [6]
Stress-induced-phosphoprotein 1 (STIP1) OT7TXLOX STIP1_HUMAN Increases Expression [7]
Syndecan-2 (SDC2) OTEEHY1D SDC2_HUMAN Increases Expression [46]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Phosphorylation [10]
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7) OTXYSIIV PTN7_HUMAN Increases Expression [7]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [7]
Fibrillin-1 (FBN1) OTYCJT63 FBN1_HUMAN Increases Expression [46]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [52]
Pigment epithelium-derived factor (SERPINF1) OTWZH98J PEDF_HUMAN Increases Expression [46]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [76]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [77]
Collagen alpha-1(XVIII) chain (COL18A1) OTJFUH6O COIA1_HUMAN Increases Expression [46]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Activity [78]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [68]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [79]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Activity [80]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Expression [81]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [82]
Isocitrate dehydrogenase , mitochondrial (IDH2) OTTQA4PB IDHP_HUMAN Decreases Expression [6]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) OTNWHUJ1 AL9A1_HUMAN Increases Expression [7]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Expression [47]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Increases Expression [83]
Caspase-4 (CASP4) OTVQTV1L CASP4_HUMAN Increases Expression [34]
NADH dehydrogenase flavoprotein 1, mitochondrial (NDUFV1) OTEVK4WW NDUV1_HUMAN Decreases Expression [6]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [84]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Decreases Expression [47]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Expression [7]
Cyclin-dependent kinase 7 (CDK7) OTAO19PQ CDK7_HUMAN Increases Activity [85]
Palmitoyl-protein thioesterase 1 (PPT1) OTM3S4DE PPT1_HUMAN Decreases Expression [47]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Decreases Expression [6]
Matrix metalloproteinase-16 (MMP16) OTSFQ2BJ MMP16_HUMAN Decreases Expression [34]
Caspase-5 (CASP5) OT0F2THD CASP5_HUMAN Increases Expression [34]
Cyclin-H (CCNH) OTKDU3SR CCNH_HUMAN Increases Expression [7]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Decreases Expression [7]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [46]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Expression [34]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [34]
Cadherin-11 (CDH11) OTIZKPTF CAD11_HUMAN Increases Expression [46]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [46]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [69]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Activity [86]
Eukaryotic initiation factor 4A-I (EIF4A1) OTMTBX6N IF4A1_HUMAN Decreases Expression [7]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [87]
Ras-related C3 botulinum toxin substrate 1 (RAC1) OTKRO61U RAC1_HUMAN Decreases Expression [6]
SH3 domain-binding protein 2 (SH3BP2) OT90JNBS 3BP2_HUMAN Decreases Expression [7]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Decreases Expression [6]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Expression [7]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [68]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [29]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [48]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Increases Expression [29]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Affects Localization [58]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [9]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [34]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [37]
Heat shock protein beta-3 (HSPB3) OTE67YM5 HSPB3_HUMAN Increases Expression [7]
Lymphocyte cytosolic protein 2 (LCP2) OT57KE22 LCP2_HUMAN Increases Expression [7]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Increases Expression [34]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) OTS3FVTY M3K1_HUMAN Increases Cleavage [80]
MAGUK p55 subfamily member 3 (MPP3) OTNOL0HA MPP3_HUMAN Increases Expression [7]
Rho-associated protein kinase 1 (ROCK1) OTSXYVW1 ROCK1_HUMAN Increases Expression [6]
Short transient receptor potential channel 3 (TRPC3) OTNR61OD TRPC3_HUMAN Increases Expression [7]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) OTTUU92F ENPP2_HUMAN Increases Expression [46]
Protein-tyrosine kinase 6 (PTK6) OT7NWIQ0 PTK6_HUMAN Increases Expression [6]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Increases Expression [55]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Increases Expression [7]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Decreases Expression [7]
Caprin-1 (CAPRIN1) OTEJAMS3 CAPR1_HUMAN Decreases Expression [34]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [34]
Periostin (POSTN) OTWP62UA POSTN_HUMAN Increases Expression [46]
Procollagen C-endopeptidase enhancer 1 (PCOLCE) OTJXOAN4 PCOC1_HUMAN Increases Expression [46]
Transcription factor E2F5 (E2F5) OT1XWING E2F5_HUMAN Increases Expression [6]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Decreases Localization [88]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [9]
Transcriptional regulator QRICH1 (QRICH1) OTPVAX04 QRIC1_HUMAN Increases Phosphorylation [89]
Parafibromin (CDC73) OT6JASZ1 CDC73_HUMAN Decreases Expression [34]
Inactive caspase-12 (CASP12) OTY2W6FG CASPC_HUMAN Decreases Expression [48]
Heme A synthase COX15 (COX15) OTUIYHIW COX15_HUMAN Decreases Expression [6]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [90]
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [34]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2) OT5Q6SVK SIR2_HUMAN Decreases Expression [52]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Increases Expression [49]
Phospholipid-transporting ATPase ABCA7 (ABCA7) OT51S50X ABCA7_HUMAN Increases Expression [29]
Centromere protein S (CENPS) OTZ4J391 CENPS_HUMAN Increases Expression [34]
NAD-dependent protein deacylase sirtuin-6 (SIRT6) OTF755ZO SIR6_HUMAN Decreases Expression [52]
Cholesterol transporter ABCA5 (ABCA5) OT4B9D92 ABCA5_HUMAN Increases Expression [29]
MAP kinase-activating death domain protein (MADD) OTUFYVGG MADD_HUMAN Decreases Expression [6]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [91]
Rap guanine nucleotide exchange factor 5 (RAPGEF5) OT53VS75 RPGF5_HUMAN Increases Expression [7]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Decreases Expression [10]
Transcription factor AP-2 gamma (TFAP2C) OTUDIW05 AP2C_HUMAN Decreases Expression [46]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [34]
Engulfment and cell motility protein 3 (ELMO3) OTQHO9VM ELMO3_HUMAN Increases Expression [7]
p53 apoptosis effector related to PMP-22 (PERP) OTP0YL53 PERP_HUMAN Increases Expression [34]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [92]
Cell division cycle 5-like protein (CDC5L) OTTPFUU5 CDC5L_HUMAN Decreases Expression [34]
M-phase phosphoprotein 6 (MPHOSPH6) OT6E2S48 MPH6_HUMAN Decreases Expression [7]
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) OTUKPFOK ROAA_HUMAN Decreases Expression [6]
Transmembrane protein 243 (TMEM243) OT8NQ79G TM243_HUMAN Increases Expression [93]
Cell division cycle-associated protein 7 (CDCA7) OT12HDZY CDCA7_HUMAN Decreases Expression [34]
Transmembrane gamma-carboxyglutamic acid protein 4 (PRRG4) OT2SZQI7 TMG4_HUMAN Decreases Expression [46]
TRIO and F-actin-binding protein (TRIOBP) OTGB5WHC TARA_HUMAN Increases Expression [7]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Decreases Expression [29]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Decreases Expression [7]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Expression [48]
NAD-dependent protein deacetylase sirtuin-7 (SIRT7) OT5M4OT4 SIR7_HUMAN Decreases Expression [52]
Olfactomedin-like protein 3 (OLFML3) OTDN45FN OLFL3_HUMAN Increases Expression [46]
G2 and S phase-expressed protein 1 (GTSE1) OTPP742Z GTSE1_HUMAN Increases Expression [7]
ETS homologous factor (EHF) OTY6TPWD EHF_HUMAN Decreases Expression [46]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Increases Expression [94]
DNA polymerase kappa (POLK) OTKZ38JH POLK_HUMAN Decreases Expression [6]
Protein Hook homolog 1 (HOOK1) OTTTKV7V HOOK1_HUMAN Decreases Expression [46]
PR domain zinc finger protein 4 (PRDM4) OTD9PAZJ PRDM4_HUMAN Decreases Expression [7]
F-box only protein 5 (FBXO5) OTTR957W FBX5_HUMAN Affects Expression [53]
Neurabin-1 (PPP1R9A) OTJL2TOC NEB1_HUMAN Decreases Expression [6]
Matrix metalloproteinase-17 (MMP17) OT5TMIQ6 MMP17_HUMAN Decreases Expression [34]
Microtubule-associated protein RP/EB family member 3 (MAPRE3) OTSCLETV MARE3_HUMAN Affects Localization [88]
Cyclin-D-binding Myb-like transcription factor 1 (DMTF1) OTDKO9OO DMTF1_HUMAN Decreases Expression [6]
RuvB-like 2 (RUVBL2) OTGWJ4T4 RUVB2_HUMAN Decreases Expression [7]
C-type lectin domain family 11 member A (CLEC11A) OT9KBH7C CLC11_HUMAN Increases Expression [46]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) OTND26XR TN13B_HUMAN Increases Expression [34]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [6]
Protein-arginine deiminase type-2 (PADI2) OTT40K94 PADI2_HUMAN Decreases Expression [7]
Mitochondrial import inner membrane translocase subunit Tim22 (TIMM22) OTJMHX1V TIM22_HUMAN Increases Expression [7]
Small ribosomal subunit protein mS40 (MRPS18B) OT1K9PFX RT18B_HUMAN Decreases Expression [7]
Transforming acidic coiled-coil-containing protein 3 (TACC3) OTRNEZTA TACC3_HUMAN Decreases Expression [7]
Sorting nexin-10 (SNX10) OT05B7BT SNX10_HUMAN Affects Response To Substance [12]
Superoxide dismutase (SOD2) OT08HOR5 Q4ZJI1_HUMAN Increases ADR [4]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Affects Response To Substance [12]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Response To Substance [95]
Phospholipid phosphatase 1 (PLPP1) OT0IIMI5 PLPP1_HUMAN Decreases Response To Substance [96]
Interleukin-17 receptor B (IL17RB) OT0KDNSF I17RB_HUMAN Decreases Response To Substance [96]
Oxysterol-binding protein-related protein 10 (OSBPL10) OT0TFMBE OSB10_HUMAN Affects Response To Substance [12]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13) OT0UOKIT NDUAD_HUMAN Affects Response To Substance [12]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [12]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Response To Substance [97]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Affects Response To Substance [12]
Integrin beta-5 (ITGB5) OT21MF51 ITB5_HUMAN Decreases Response To Substance [32]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7) OT2CHQQ1 NDUB7_HUMAN Affects Response To Substance [12]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [12]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25) OT2MR6O2 SNR25_HUMAN Affects Response To Substance [12]
Epidermal growth factor-like protein 6 (EGFL6) OT331X59 EGFL6_HUMAN Decreases Response To Substance [15]
Biglycan (BGN) OT3AV6IF PGS1_HUMAN Affects Response To Substance [12]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Affects Response To Substance [98]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Increases Response To Substance [96]
Solute carrier family 12 member 2 (SLC12A2) OT3ZJ3LH S12A2_HUMAN Decreases Response To Substance [96]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Response To Substance [12]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Affects Response To Substance [12]
Deoxycytidylate deaminase (DCTD) OT4FLFT4 DCTD_HUMAN Affects Response To Substance [12]
Sorcin (SRI) OT4R3EAC SORCN_HUMAN Decreases Response To Substance [99]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Affects Response To Substance [55]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [12]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Increases Response To Substance [100]
Small ribosomal subunit protein uS15m (MRPS15) OT5HRAPP RT15_HUMAN Affects Response To Substance [12]
RAC-gamma serine/threonine-protein kinase (AKT3) OT5M2LFI AKT3_HUMAN Affects Response To Substance [75]
Signal recognition particle receptor subunit alpha (SRPRA) OT5NMYTY SRPRA_HUMAN Affects Response To Substance [12]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Increases Response To Substance [96]
Beta-sarcoglycan (SGCB) OT5R5LAT SGCB_HUMAN Affects Response To Substance [12]
Collagen alpha-2(V) chain (COL5A2) OT5VOSQE CO5A2_HUMAN Decreases Response To Substance [15]
Transmembrane protein 135 (TMEM135) OT63ZT3X TM135_HUMAN Affects Response To Substance [12]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Increases Response To Substance [32]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Decreases Response To Substance [32]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Increases Response To Substance [32]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Decreases Response To Substance [96]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [12]
DNA-binding protein RFX5 (RFX5) OT73KJ5P RFX5_HUMAN Decreases Response To Substance [32]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [101]
Large ribosomal subunit protein P1 (RPLP1) OT7B0SIB RLA1_HUMAN Decreases Response To Substance [32]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Decreases Response To Substance [102]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Affects Response To Substance [12]
Peroxisomal multifunctional enzyme type 2 (HSD17B4) OT8733D7 DHB4_HUMAN Affects Response To Substance [12]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Response To Substance [103]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [104]
Thrombomodulin (THBD) OT8VHLKY TRBM_HUMAN Decreases Response To Substance [105]
Transcriptional repressor CTCF (CTCF) OT8ZB70U CTCF_HUMAN Decreases Response To Substance [32]
Neuron navigator 3 (NAV3) OT97M1TR NAV3_HUMAN Affects Response To Substance [12]
Solute carrier family 22 member 18 (SLC22A18) OT9C3KR4 S22AI_HUMAN Decreases Response To Substance [96]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30) OT9DERT1 GILT_HUMAN Decreases Response To Substance [32]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Response To Substance [32]
Beta-glucuronidase (GUSB) OT9N1DK3 BGLR_HUMAN Affects Response To Substance [12]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Response To Substance [32]
Proteasome subunit beta type-6 (PSMB6) OT9VXPNW PSB6_HUMAN Affects Response To Substance [12]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [12]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Response To Substance [32]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [12]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Response To Substance [106]
Proteasome subunit alpha type-4 (PSMA4) OTAD2XXI PSA4_HUMAN Affects Response To Substance [12]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [12]
Mediator of RNA polymerase II transcription subunit 4 (MED4) OTALFN4S MED4_HUMAN Affects Response To Substance [12]
snRNA-activating protein complex subunit 1 (SNAPC1) OTAPN1NI SNPC1_HUMAN Increases Response To Substance [96]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Affects Response To Substance [12]
MAP kinase-activated protein kinase 5 (MAPKAPK5) OTAZHPVK MAPK5_HUMAN Affects Response To Substance [12]
Desmoplakin (DSP) OTB2MOP8 DESP_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein mL40 (MRPL40) OTB2QZDY RM40_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein uL16 (RPL10) OTBHOZGC RL10_HUMAN Affects Response To Substance [12]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Response To Substance [107]
Probable ATP-dependent RNA helicase DDX23 (DDX23) OTBJHS8C DDX23_HUMAN Affects Response To Substance [12]
Coatomer subunit epsilon (COPE) OTBKHBT7 COPE_HUMAN Affects Response To Substance [12]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Affects Response To Substance [12]
Transmembrane protein 134 (TMEM134) OTBX9H9D TM134_HUMAN Affects Response To Substance [12]
Tight junction protein ZO-3 (TJP3) OTC1K8HC ZO3_HUMAN Decreases Response To Substance [96]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Affects Response To Substance [108]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Affects Response To Substance [12]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [12]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Increases Response To Substance [32]
S-phase kinase-associated protein 2 (SKP2) OTD5B41X SKP2_HUMAN Affects Response To Substance [12]
Integrin alpha-1 (ITGA1) OTDITIST ITA1_HUMAN Increases Response To Substance [15]
Stathmin (STMN1) OTDJ4RV0 STMN1_HUMAN Affects Response To Substance [109]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [12]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Response To Substance [32]
Superkiller complex protein 8 (SKIC8) OTDSQYDN SKI8_HUMAN Affects Response To Substance [12]
DNA-binding protein RFXANK (RFXANK) OTDX1026 RFXK_HUMAN Affects Response To Substance [12]
Transcription initiation factor TFIID subunit 1 (TAF1) OTDYS5G4 TAF1_HUMAN Affects Response To Substance [110]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7) OTE0EG10 EFCB7_HUMAN Affects Response To Substance [12]
Glucose-6-phosphate isomerase (GPI) OTEGSRXG G6PI_HUMAN Affects Response To Substance [12]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR) OTEOT8GI GFRP_HUMAN Decreases Response To Substance [96]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13) OTESFZSO PTN13_HUMAN Increases Response To Substance [96]
Rho GDP-dissociation inhibitor 1 (ARHGDIA) OTEXWJDO GDIR1_HUMAN Affects Response To Substance [111]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Response To Substance [32]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [12]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Affects Response To Substance [12]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Increases Response To Substance [15]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [12]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [12]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Affects Response To Substance [12]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Affects Response To Substance [55]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Affects Response To Substance [12]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Response To Substance [14]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Response To Substance [112]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Response To Substance [32]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Decreases Response To Substance [113]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [12]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [12]
Polycystin-2 (PKD2) OTIXBU8H PKD2_HUMAN Increases Response To Substance [96]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Affects Response To Substance [12]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [12]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Decreases Response To Substance [96]
Transmembrane protein 168 (TMEM168) OTJKZ6G9 TM168_HUMAN Affects Response To Substance [12]
Plakophilin-2 (PKP2) OTJOVF68 PKP2_HUMAN Decreases Response To Substance [96]
C-X-C chemokine receptor type 6 (CXCR6) OTK9R50G CXCR6_HUMAN Decreases Response To Substance [32]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Response To Substance [96]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Response To Substance [12]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Response To Substance [96]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases ADR [4]
Galectin-4 (LGALS4) OTKQCG0H LEG4_HUMAN Decreases Response To Substance [96]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Affects Response To Substance [12]
Leukocyte surface antigen CD47 (CD47) OTLDZ0KZ CD47_HUMAN Decreases Response To Substance [32]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Affects Response To Substance [12]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Increases Response To Substance [97]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [14]
Peptidyl-prolyl cis-trans isomerase B (PPIB) OTLPH6KN PPIB_HUMAN Affects Response To Substance [12]
Annexin A8 (ANXA8) OTLSSQCY ANXA8_HUMAN Increases Response To Substance [96]
Keratin, type II cytoskeletal 7 (KRT7) OTLT3JFN K2C7_HUMAN Increases Response To Substance [96]
Lysosome-associated membrane glycoprotein 2 (LAMP2) OTLUGEJC LAMP2_HUMAN Affects Response To Substance [12]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Affects Response To Substance [12]
Hemicentin-1 (HMCN1) OTLZAS0P HMCN1_HUMAN Increases Response To Substance [15]
Furin (FURIN) OTM2665Z FURIN_HUMAN Decreases Response To Substance [32]
NADH dehydrogenase iron-sulfur protein 8, mitochondrial (NDUFS8) OTMEAWKO NDUS8_HUMAN Affects Response To Substance [12]
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) OTMFG2YY ALG8_HUMAN Affects Response To Substance [12]
Glutathione S-transferase Mu 5 (GSTM5) OTMMBFY8 GSTM5_HUMAN Decreases Response To Substance [32]
Unconventional myosin-Va (MYO5A) OTMWLP3E MYO5A_HUMAN Increases Response To Substance [96]
Integral membrane protein 2B (ITM2B) OTMXEPXB ITM2B_HUMAN Affects Response To Substance [12]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2) OTMZD4PW SUCB1_HUMAN Affects Response To Substance [12]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Increases Response To Substance [96]
L-lactate dehydrogenase A chain (LDHA) OTN7K4XB LDHA_HUMAN Increases Response To Substance [114]
Proto-oncogene serine/threonine-protein kinase mos (MOS) OTNMQPFJ MOS_HUMAN Increases ADR [4]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases ADR [4]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1) OTNYXOZO KCMA1_HUMAN Affects Response To Substance [12]
G-protein coupled receptor 35 (GPR35) OTO23NRK GPR35_HUMAN Decreases Response To Substance [96]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Increases Response To Substance [96]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Response To Substance [115]
Arginine/serine-rich protein 1 (RSRP1) OTOAZLCL RSRP1_HUMAN Affects Response To Substance [12]
Malectin (MLEC) OTOPGRF5 MLEC_HUMAN Affects Response To Substance [12]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Increases Response To Substance [96]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Response To Substance [116]
Delta(24)-sterol reductase (DHCR24) OTP301JW DHC24_HUMAN Affects Response To Substance [12]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [12]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [12]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein uL23 (RPL23A) OTPYLCCX RL23A_HUMAN Decreases Response To Substance [32]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Response To Substance [32]
Eukaryotic translation initiation factor 5A-1 (EIF5A) OTQ8DJX5 IF5A1_HUMAN Increases Response To Substance [96]
Membrane cofactor protein (CD46) OTQ8NWJD MCP_HUMAN Increases Response To Substance [32]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1) OTQBDO45 GFPT1_HUMAN Decreases Response To Substance [96]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Decreases Response To Substance [117]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [12]
Keratin, type I cytoskeletal 23 (KRT23) OTQW6UAG K1C23_HUMAN Increases Response To Substance [15]
Fibroblast growth factor 5 (FGF5) OTQXGHBY FGF5_HUMAN Affects Response To Substance [12]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Affects Response To Substance [12]
Nuclear body protein SP140 (SP140) OTQZHFMT SP140_HUMAN Affects Response To Substance [12]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Response To Substance [15]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [118]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [12]
Protein CREG1 (CREG1) OTRHJ8HK CREG1_HUMAN Affects Response To Substance [12]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) OTRHPFO2 AN32A_HUMAN Affects Response To Substance [12]
Retinol-binding protein 1 (RBP1) OTRP1MFC RET1_HUMAN Increases Response To Substance [96]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Response To Substance [96]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Increases Response To Substance [96]
Arrestin-C (ARR3) OTRZ00CH ARRC_HUMAN Decreases Response To Substance [32]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Response To Substance [96]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [12]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B) OTS9YK3E KCC2B_HUMAN Affects Response To Substance [12]
Lumican (LUM) OTSRC874 LUM_HUMAN Decreases Response To Substance [15]
Rhotekin (RTKN) OTSS8XR6 RTKN_HUMAN Decreases Response To Substance [119]
3-phosphoinositide-dependent protein kinase 1 (PDPK1) OTT09ZVP PDPK1_HUMAN Decreases Response To Substance [103]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [12]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Response To Substance [15]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [12]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [120]
Amyloid beta precursor like protein 2 (APLP2) OTTFE53M APLP2_HUMAN Affects Response To Substance [12]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Decreases Response To Substance [15]
Fascin (FSCN1) OTTGIHTM FSCN1_HUMAN Increases Response To Substance [96]
Keratin, type I cytoskeletal 13 (KRT13) OTTYSKGX K1C13_HUMAN Decreases Response To Substance [32]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Decreases Response To Substance [121]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Response To Substance [32]
N-acetylgalactosaminyltransferase 7 (GALNT7) OTUJSCAO GALT7_HUMAN Affects Response To Substance [12]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (DAD1) OTUUNQBT DAD1_HUMAN Increases ADR [4]
Mitochondrial Rho GTPase 2 (RHOT2) OTV8WT2L MIRO2_HUMAN Affects Response To Substance [12]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Decreases Response To Substance [15]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [14]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Response To Substance [12]
U2 small nuclear ribonucleoprotein A' (SNRPA1) OTWJZFAP RU2A_HUMAN Affects Response To Substance [12]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Response To Substance [15]
Glypican-3 (GPC3) OTWS8WSW GPC3_HUMAN Increases Response To Substance [15]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Response To Substance [122]
Transmembrane protein 59 (TMEM59) OTX4EKES TMM59_HUMAN Affects Response To Substance [12]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15) OTX8SZOT NUD15_HUMAN Affects Response To Substance [12]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Increases Response To Substance [32]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3) OTXL10N9 NDUA3_HUMAN Affects Response To Substance [12]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [104]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [12]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Decreases Response To Substance [32]
Collagen alpha-2(I) chain (COL1A2) OTY7G382 CO1A2_HUMAN Increases Response To Substance [15]
Bone morphogenetic protein 7 (BMP7) OTYATP2K BMP7_HUMAN Increases Response To Substance [32]
Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PPP1CB) OTYFTYFR PP1B_HUMAN Affects Response To Substance [12]
Ferritin light chain (FTL) OTYQA8A6 FRIL_HUMAN Decreases Response To Substance [32]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Response To Substance [12]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Increases Response To Substance [32]
ADP-ribosylation factor 3 (ARF3) OTYYQX85 ARF3_HUMAN Affects Response To Substance [12]
V-type proton ATPase catalytic subunit A (ATP6V1A) OTYZ2S9E VATA_HUMAN Affects Response To Substance [12]
Mitochondrial import inner membrane translocase subunit Tim13 (TIMM13) OTYZQJD3 TIM13_HUMAN Affects Response To Substance [12]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Decreases Response To Substance [123]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [12]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Affects Response To Substance [12]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 478 DOT(s)

References

1 ClinicalTrials.gov (NCT02824575) Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
2 Paclitaxel FDA Label
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
6 Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
7 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
8 Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res. 2008 May-Jun;28(3A):1593-602.
9 Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
10 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
11 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006 Jan 8;231(1):49-64. doi: 10.1016/j.canlet.2005.01.018.
12 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
13 Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
14 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
15 Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
16 Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011 Jan 26;3(67):67ra7. doi: 10.1126/scitranslmed.3001922.
17 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
18 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
19 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
20 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
21 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
22 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
23 Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
24 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
25 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
26 Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
27 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
28 FaDu cell characteristics induced by multidrug resistance. Oncol Rep. 2011 Nov;26(5):1189-95. doi: 10.3892/or.2011.1418. Epub 2011 Aug 10.
29 Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
30 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
31 Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004 Nov 15;64(22):8397-404. doi: 10.1158/0008-5472.CAN-04-1612.
32 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
33 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
34 Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
35 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
36 Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
37 Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
38 CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
39 A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology. 2004 Apr;145(4):1860-9.
40 The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 2005 May;19(5):1170-80.
41 Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1). Res Commun Mol Pathol Pharmacol. 2004;115-116:21-38.
42 Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009 Jun 16;53(24):2298-305.
43 Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
44 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
45 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
46 Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
47 Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells. Chem Res Toxicol. 2019 Feb 18;32(2):255-264. doi: 10.1021/acs.chemrestox.8b00269. Epub 2019 Jan 22.
48 Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
49 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
50 Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
51 Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton. PLoS One. 2011;6(6):e20707. doi: 10.1371/journal.pone.0020707. Epub 2011 Jun 27.
52 Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression. Environ Toxicol. 2021 Nov;36(11):2206-2216. doi: 10.1002/tox.23334. Epub 2021 Jul 16.
53 CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
54 Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact. 2020 Jan 5;315:108865. doi: 10.1016/j.cbi.2019.108865. Epub 2019 Oct 16.
55 The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
56 The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol. 2009 May;25(5):287-93. doi: 10.1080/09513590802530924.
57 Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2003 Apr;42(5):419-29. doi: 10.1016/s0197-0186(02)00132-8.
58 Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
59 Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7;25(3):94-102. doi: 10.1016/j.cyto.2003.10.004.
60 Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
61 pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
62 Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
63 Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol. 2014 May;29(7):804-13. doi: 10.1002/tox.21809. Epub 2012 Aug 21.
64 ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 2004 Jun;24(6):1499-504.
65 Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 1999 Mar 19;274(12):8208-16. doi: 10.1074/jbc.274.12.8208.
66 Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
67 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
68 Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. J Biochem Mol Toxicol. 2023 May;37(5):e23313. doi: 10.1002/jbt.23313. Epub 2023 Jan 22.
69 Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
70 Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
71 Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
72 Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res. 2003 Jun;9(6):2366-73.
73 Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999 Jul;5(7):1876-83.
74 Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.
75 Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008 Feb;13(2):259-71. doi: 10.1007/s10495-007-0165-6.
76 Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
77 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
78 Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci. 2010 May;115(1):118-30. doi: 10.1093/toxsci/kfq028. Epub 2010 Jan 27.
79 Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res. 2005 Sep;23(5):988-94. doi: 10.1016/j.orthres.2005.01.018. Epub 2005 Apr 25.
80 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol. 2001 Feb;59(2):254-62. doi: 10.1124/mol.59.2.254.
81 Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):55-62. doi: 10.1016/j.taap.2005.06.020. Epub 2005 Jul 26.
82 Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol. 2005 Jul 1;70(1):13-21. doi: 10.1016/j.bcp.2005.04.017.
83 Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
84 PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009 Apr 15;77(8):1348-57. doi: 10.1016/j.bcp.2009.01.008. Epub 2009 Jan 24.
85 Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2(5):463-70. doi: 10.1023/a:1026422111457.
86 Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs. 2001 Nov;12(10):797-800. doi: 10.1097/00001813-200111000-00002.
87 Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
88 Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.
89 Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
90 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
91 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol. 2001 Jun;6(3):128-31. doi: 10.1007/pl00012094.
92 Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006 Apr;5(4):380-5. doi: 10.4161/cbt.5.4.2477. Epub 2006 Apr 4.
93 MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene. 2004 Sep 29;340(1):53-9. doi: 10.1016/j.gene.2004.06.013.
94 Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
95 High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010 Jul 1;70(13):5486-96. doi: 10.1158/0008-5472.CAN-10-0713. Epub 2010 Jun 8.
96 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
97 E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
98 Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
99 [Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]. Ai Zheng. 2008 Apr;27(4):337-42.
100 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
101 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
102 Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. doi: 10.1007/s11095-006-0136-6. Epub 2006 Jun 8.
103 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
104 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
105 Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016 Jul 15;365:48-58. doi: 10.1016/j.tox.2016.07.016. Epub 2016 Jul 27.
106 CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.
107 CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mllerian tumor). Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.
108 ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. Toxicology. 2021 Aug;460:152890. doi: 10.1016/j.tox.2021.152890. Epub 2021 Aug 6.
109 Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
110 MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. doi: 10.1002/jbt.23380. Epub 2023 May 3.
111 Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs. 2007 Mar;18(3):333-40. doi: 10.1097/CAD.0b013e328011fd7f.
112 Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011 Jun 13.
113 Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environ Toxicol. 2021 Sep;36(9):1758-1764. doi: 10.1002/tox.23296. Epub 2021 May 28.
114 Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011 Mar 24;54(6):1599-612. doi: 10.1021/jm101007q. Epub 2011 Feb 18.
115 Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells. Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.
116 Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
117 Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
118 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
119 Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004 Nov 18;23(54):8731-42. doi: 10.1038/sj.onc.1208106.
120 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
121 Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 1;9(6):681-9. doi: 10.6004/jnccn.2011.0056.
122 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
123 Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis. 2006 Dec;24(3):525-30. doi: 10.1016/j.nbd.2006.08.014. Epub 2006 Sep 28.